Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia-Reference-Cited by-同舟云学术

Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia

Published:2020-05-14 Issue:2 Volume:35 Page:585-594
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Lorentino Francesca, ,Labopin Myriam,Ciceri Fabio,Vago Luca^ORCID,Fleischhauer Katharina,Afanasyev Boris,Kröger Nicolaus,Cornelissen Jan J.,Lovira Montserrat,Meijer Ellen,Vitek Antonin,Elmaagacli Ahmet,Blaise Didier^ORCID,Ruggeri Annalisa,Chabannon Christian^ORCID,Nagler Arnon,Mohty Mohamad

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-020-0863-4.pdf

Reference60 articles.

1. Thomas ED. Marrow transplantation for malignant disease. Am J Med Sci. 1987;294:75–9.

2. Kollman C, Spellman SR, Zhang M-J, Hassebroek A, Anasetti C, Antin JH, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016;127:260–7.

3. Nakasone H, Remberger M, Tian L, Brodin P, Sahaf B, Wu F, et al. Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. Haematologica. 2015;100:1477–85.

4. Shaw BE, Mayor NP, Szydlo RM, Bultitude WP, Anthias C, Kirkland K, et al. Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants. Bone Marrow Transpl. 2017;52:717–25.

5. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110:4576–83.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Young (<35 years) haploidentical versus old (≥35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation;Bone Marrow Transplantation;2024-08-18

2. Tacrolimus versus cyclosporine a combined with post-transplantation cyclophosphamide for AML In first complete remission: a study from the acute leukemia working party (EBMT);Bone Marrow Transplantation;2024-07-03

3. Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post‐transplant cyclophosphamide versus conventional anti‐graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation;American Journal of Hematology;2024-06-10

4. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation;Bone Marrow Transplantation;2024-04-13

5. Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification;Blood Reviews;2023-11